ASH 2020

Area: Hematology

Location: Online, Virtual

Date: December 5 to December 8


Search in Scientific Content:
Date
Filters:
Effect of
4:54

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin on Patients with Relapsed/Refractory Classical Hodgkin Lymphoma: Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

Presenter: John Kuruvilla
Hematology
Optimal Du
3:55

Optimal Duration of Imatinib Treatment / Deep Molecular Response for Treatment-Free Remission after Imatinib Discontinuation from a Canadian Tyrosine Kinase Inhibitor Discontinuation Trial

Presenter: Dennis Kim
Hematology
Novelties
8:45

Novelties on the treatment of Multiple Myeloma and Plasma Cell Disorders

Presenter: Joseph Mikhael
Hematology
Comprehens
14:08

Comprehensive summary of novel multiple myeloma data from ASH2020

Presenter: Andrzej Jakubowiak
Hematology
Comparison
7:32

Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

Presenter: Amer Zeidan
Hematology
Polatuzuma
5:05

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Presenter: Giuseppe Gritti
Hematology
Highlights
9:15

Highlights of the Late-Breaking Abstracts Session of ASH 2020

Presenter: Christopher Flowers
Hematology
Ruxolitini
5:24

Ruxolitinib Vs Best Available Therapy in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease: Primary Findings from the Phase 3, Randomized REACH3 Study

Presenter: Robert Zeiser
Hematology
What are t
3:32

What are the trends in lymphoma therapy?

Presenter: Catherine Diefenbach
Hematology
Effects of
11:38

Effects of Tranexamic Acid Prophylaxis on Bleeding Outcomes in Hematologic Malignancy: The a-TREAT Trial

Presenter: Darrell Triulzi
Hematology
A Multi-Ce
3:33

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplan

Presenter: Corey Cutler
Hematology
Discovery
3:50

Discovery of biomarkers for targeted therapy in B cell lymphoma

Presenter: Min Xia
Hematology
Newly Diag...
5:44

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children’s Oncology Group AAML1031 Protocol

Presenter: Lisa Eidenschink Brodersen
Hematology
Acute Myel
3:19

Acute Myeloid Leukemia: Using Available Evidence and Guidelines to Make Sense of a Rapidly Evolving Treatment Paradigm

Presenter: Farhad Ravandi
Hematology
The Immune
6:50

The Immune System in Multiple Myeloma

Presenter: Saad Z. Usmani
Hematology
Efficacy a...
10:41

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Previously Treated with ≥2 Tyrosine Kinase Inhibitor

Presenter: Andreas Hochhaus
Hematology

ASH 2017

2017-12-09 - 2017-12-12
Atlanta, United States

EHA 2017

2017-06-22 - 2017-06-25
Madrid, Spain

ICML 2017

2017-06-14 - 2017-06-17
Lugano, Switzerland

ASH 2016

2016-12-03 - 2016-12-06
San Diego, United States

ASH 2015

2015-12-05 - 2015-12-08
Orlando, United States

EHA 2015

2015-06-11 - 2015-06-14
Vienna, Australia